Amplio Pharma
Amsterdam, North Holland, Netherlands · Biotechnology, Health Care, Medical
Amplio Pharma is a clinical-stage pharmaceutical company focused on developing NovoBioJect to enhance the first-line treatment of rheumatoid arthritis (RA). Their innovative approach combines low-dose methotrexate with novobiocin to improve drug retention in immune cells. This aims to offer a potential next-generation treatment for patients who do not achieve remission with standard therapies. Amp
Key facts
- Headquarters
- Amsterdam, North Holland, Netherlands
- Employees
- 9
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- amplio-pharma.com
- Company page
Recent activity at Amplio Pharma
Amplio Pharma funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Series A | $10.0M |
Amplio Pharma in the news
Companies similar to Amplio Pharma
- Lipella Pharmaceuticals · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- OncoZenge AB · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Bio-Convert ApS · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Aculys Pharma · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Delta-Fly Pharma · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Amplio Pharma: questions and answers
What does Amplio Pharma do?
Amplio Pharma is a clinical-stage pharmaceutical company focused on developing NovoBioJect to enhance the first-line treatment of rheumatoid arthritis (RA). Their innovative approach combines low-dose methotrexate with novobiocin to improve drug retention in immune cells. This aims to offer a potential next-generation treatment for patients who do not achieve remission with standard therapies. Amp
Where is Amplio Pharma headquartered?
Amplio Pharma is headquartered in Amsterdam, North Holland, Netherlands.
How many employees does Amplio Pharma have?
Amplio Pharma has about 9 employees.
Has Amplio Pharma raised funding?
Yes. Fundz has recorded 1 funding event for Amplio Pharma. The most recent, Series A of $10.0M, was in Oct 2026.
What is the latest news on Amplio Pharma?
On Oct 01, 2026, Amplio Pharma initiates Series A financing of approximately €10 million to advance NovoBioJect, a next-generation rheumatoid arthritis treatment, into Phase 2a trials.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy